3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
8
Carcinoma, Merkel Cell
6
Neoplasm Metastasis
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Penile Squamous Cell Carcinoma (PSCC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
17
fludarabine phosphate
12
pembrolizumab
11
Brentuximab Vedotin
11
Nivolumab
10
Mycophenolic Acid
10
fludarabine
9
Doxorubicin
9
Dacarbazine
9
Whole-Body Irradiation
8
Vinblastine
7
Magnetic Resonance Spectroscopy
7
Filgrastim
7
Etoposide
7
Cyclosporine
7
Specimen Handling
6
Sirolimus
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Busulfan
5
Tacrolimus
4
Gemcitabine
4
pegfilgrastim
3
Vinorelbine
3
Radiation
3
Cyclosporins
3
Carmustine
3
thymoglobulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
avelumab
×
90 days
×
Clear all
No trials found.